Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

163
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
163
Protein-protein Interfaces02:04

Protein-protein Interfaces

12.5K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.5K
Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

523
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
523
Protein Complexes with Interchangeable Parts01:57

Protein Complexes with Interchangeable Parts

2.5K
Groups of proteins may form a complex where each protein in this complex has a different role in the overall execution of the complex’s function. Often some of the proteins in the complex can be replaced by a closely related variant to give a complex that contains many of the same components yet is functionally distinct.
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order...
2.5K
Factors Affecting Protein-Drug Binding: Protein-Related Factors01:20

Factors Affecting Protein-Drug Binding: Protein-Related Factors

167
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
167
Protein Networks02:26

Protein Networks

4.0K
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nuclear import of malaria RNA rewires splicing in host immune cells.

Cell reports·2026
Same author

A pharmacological modality to sequester homomeric proteins.

Nature chemical biology·2026
Same author

Bridging or exchanging partners? A supramolecular perspective on bifunctional molecules and their potential for triggerable enzyme therapy.

Current opinion in chemical biology·2026
Same author

Quantification and characterization of extracellular vesicles by flow cytometry.

Current topics in membranes·2025
Same author

Polyphosphocholination of liposomic vehicles extends blood circulation, enhances cellular uptake, and lowers immunogenicity relative to PEGylation.

Journal of controlled release : official journal of the Controlled Release Society·2025
Same author

Low-Background His-Tag-Targeting Probes for Turn-On Fluorescence Detection of Cell Surface Proteins and Their Binding Interactions.

Small (Weinheim an der Bergstrasse, Germany)·2025

Related Experiment Video

Updated: Jul 10, 2025

Engineering Antiviral Agents via Surface Plasmon Resonance
13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

2.4K

Artificial Protein Crosstalk with a Molecule that Exchanges Binding Partners.

Ohad Suss1, Olga Halfin1, Ziv Porat2

  • 1Department of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, 7610001, Israel.

Angewandte Chemie (International Ed. in English)
|November 27, 2023
PubMed
Summary
This summary is machine-generated.

Scientists created a new method to control enzyme activity in cells using synthetic regulators. This approach links enzyme function to cellular oxygen levels, mimicking natural signaling pathways.

Keywords:
Artificially Activated EnzymesProtein Surface RecognitionSupramolecular Chemistry

More Related Videos

Genetic and Biochemical Approaches for In Vivo and In Vitro Assessment of Protein Oligomerization: The Ryanodine Receptor Case Study
12:43

Genetic and Biochemical Approaches for In Vivo and In Vitro Assessment of Protein Oligomerization: The Ryanodine Receptor Case Study

Published on: July 27, 2016

11.7K
Extracellular Protein Microarray Technology for High Throughput Detection of Low Affinity Receptor-Ligand Interactions
06:01

Extracellular Protein Microarray Technology for High Throughput Detection of Low Affinity Receptor-Ligand Interactions

Published on: January 7, 2019

7.3K

Related Experiment Videos

Last Updated: Jul 10, 2025

Engineering Antiviral Agents via Surface Plasmon Resonance
13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

2.4K
Genetic and Biochemical Approaches for In Vivo and In Vitro Assessment of Protein Oligomerization: The Ryanodine Receptor Case Study
12:43

Genetic and Biochemical Approaches for In Vivo and In Vitro Assessment of Protein Oligomerization: The Ryanodine Receptor Case Study

Published on: July 27, 2016

11.7K
Extracellular Protein Microarray Technology for High Throughput Detection of Low Affinity Receptor-Ligand Interactions
06:01

Extracellular Protein Microarray Technology for High Throughput Detection of Low Affinity Receptor-Ligand Interactions

Published on: January 7, 2019

7.3K

Area of Science:

  • Biochemistry
  • Synthetic Biology
  • Enzyme Engineering

Background:

  • Allosteric enzymes regulate cellular processes through non-covalent interactions between catalytic and regulatory units.
  • Understanding and mimicking these natural signaling mechanisms is crucial for developing novel therapeutic strategies.
  • Glycogen synthase kinase 3 (GSK-3) and lactate dehydrogenase A (LDHA) are key enzymes involved in cellular metabolism and response to environmental cues.

Purpose of the Study:

  • To devise a method for establishing effector-mediated, unnatural enzyme activation within native cells.
  • To demonstrate the feasibility of this approach using glycogen synthase kinase 3 (GSK-3) and lactate dehydrogenase A (LDHA).
  • To create a synthetic regulatory system that links enzyme activity to cellular oxygen levels.

Main Methods:

  • Introduction of a synthetic regulatory unit (sRU) onto GSK-3 via non-covalent attachment.
  • Engineering unnatural crosstalk between GSK-3 and LDHA.
  • Utilizing LDHA as an effector protein to control GSK-3 activity based on cellular oxygen levels.

Main Results:

  • GSK-3 was successfully transformed from a constitutively active enzyme into an activable one.
  • LDHA was repurposed as an unnatural effector, mediating GSK-3 activity in response to hypoxia.
  • Demonstrated unnatural crosstalk between GSK-3 and LDHA, controlled by cellular oxygen levels.

Conclusions:

  • This study presents a novel method for creating effector-regulated enzymes within living cells, mimicking natural allosteric signaling.
  • The findings pave the way for developing new classes of protein inhibitors whose activity is environmentally dependent.
  • This approach offers a proof-of-principle for engineering cellular responses to environmental changes through synthetic enzyme regulation.